Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Pegylated Interferon Alfa

Recombinant protein · Agonist of Interferon alpha receptor · developed by Vir Biotechnology

Phase 2 Most advanced trial (none active)
VIR Developer
1 Registered trials

What is Pegylated Interferon Alfa?

Pegylated Interferon Alfa is a covalent conjugate of recombinant interferon alpha and polyethylene glycol. It binds cell-surface interferon receptors, driving gene transcription that mediates antiviral and immune-modulating effects, and is being studied in chronic hepatitis B virus infection. The polyethylene glycol moiety extends the duration of its activity.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
PEG-IFNα
Drug type
Recombinant protein
Targets
Interferon alpha receptor
Mechanism
Agonist of Interferon alpha receptor
Pathways
JAK/STAT signaling, antiviral response, antiproliferative effects, immune modulation
Therapy area
Infectious disease
Developer
Vir Biotechnology, Inc. (VIR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06491563 Phase 2 For Treatment of Chronic Hepatitis B Virus Infection Completed VIR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

For Treatment of Chronic Hepatitis B Virus Infection

More from Vir Biotechnology

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the VIR page.

Follow VIR, the company behind Pegylated Interferon Alfa

See VIR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VIR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.